Castrate-resistant prostate cancer

M0 CRPC: Treatment Options and Emerging Concepts

M0 CRPC: Treatment Options and Emerging Concepts

Alicia K. Morgans, MD, MPH, Associate Professor of Medicine in Hematology and Oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the use of androgen receptor antagonists in treating patients with non-metastatic (M0) castrate-resistant prostate cancer (CRPC). She goes on to discuss how before these three pivotal trials, treatment for patients…

Read More